Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Randomized-controlled, Multi-center Phase-II Clinical Trial of Individualized Immunosuppression With Intravenously Administered Donor Modified Immune Cells (MIC) Compared to Standard-of-care in Living Donor Kidney Transplantation

NCT05365672 is registered in ClinicalTrials.gov with TolerogenixX GmbH as lead sponsor.

NCT NCT05365672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05365672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Randomized-controlled, Multi-center Phase-II Clinical Trial of Individualized Immunosuppression With Intravenously Administered Donor Modified Immune Cells (MIC) Compared to Standard-of-care in Living Donor Kidney Transplantation
Lead sponsor
TolerogenixX GmbH
Phase
Phase 2
Overall status
Recruiting
Start date
May 4, 2022
Completion date
December 31, 2028
Enrollment
126 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation